Balyasny Asset Management
MCRB icon

Balyasny Asset Management’s Seres Therapeutics MCRB Stock Holding History

Balyasny Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-985
Closed -$14.3K – 2994
2024
Q2 		$14.3K Buy
+985
New +$16.4K ﹤0.01% 2484
2024
Q1 		– Sell
-2,751
Closed -$77K – 2908
2023
Q4 		$77K Buy
+2,751
New +$72.2K ﹤0.01% 2397
2023
Q1 		– Sell
-387
Closed -$43.3K – 2954
2022
Q4 		$43.3K Sell
387
-377
-49% -$50.5K ﹤0.01% 2366
2022
Q3 		$98K Buy
+764
New +$78.2K ﹤0.01% 2410

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Balyasny Asset Management's MCRB Position: Q3 2024 in Review

Balyasny Asset Management sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 985 shares — an estimated $14.3K sold.

Balyasny Asset Management first reported a position in MCRB in Q3 2022 and held it in 4 quarters. The position peaked at $98K in Q3 2022. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Balyasny Asset Management reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 985 Seres Therapeutics shares in Q3 2024, an estimated $14.3K.
  • Balyasny Asset Management first reported a position in Seres Therapeutics in Q3 2022 and held it in 4 quarters.
  • Balyasny Asset Management's Seres Therapeutics position peaked at $98K in Q3 2022.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.